Are the current safety measures for the treatment of depression with esketamine sufficient?
Kyle Valentino, Kayla M Teopiz, Christine E. Dri, Jennifer Swainson, Yang Jing Zheng, Roger S McIntyre
Expert Opinion on Drug Safety February 19, 2026 DOI: 10.1080/14740338.2026.2627184 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Topics | Depression Esketamine Ketamine |
| Keywords | Rems |
Abstract
1. Esketamine as monotherapy or adjunct to conventional antidepressants is proven efficacious in clinical trials in adults with treatment-resistant depression (TRD) and depression with high risk of...
Citations in the library
Cites 11
- Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation American Journal of Psychiatry March 17, 2021
- The abuse liability of ketamine: A scoping review of preclinical and clinical studies. Journal of Psychiatric Research May 1, 2022
- Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis. Journal of Affective Disorders July 1, 2024
- Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression. European Neuropsychopharmacology August 1, 2024
- Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis Almost 5 Years After First Approval. American Journal of Psychiatry September 10, 2025
and 6 more in the library